(TSX-V:CPI),(OTC US:NBRFF),(OTCQB:NBRFF),(OTC US:CPIFF),(OtherOTC:CPIFF), TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) — Carlton Precious Inc. (TSX-V: CPI | OTCQB: CPIFF) (“Carlton” or the “Company“) is pleased to provide an update to investors on its Esquilache Silver project (“Esquilache” or the “Project”) located in the Puno region of Southern Peru. Esquilache covers 1,600 hectares that include historical mine […]
(NASDAQ:ELDN), IRVINE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will participate in a fireside chat at the upcoming 37th Annual Piper Sandler Healthcare Conference on Thursday, December 4, 2025 at 8:50 a.m. ET (5:50 a.m. PT). To register in
(NASDAQ:MGX), EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that the Company will present new preclinical data supporting the third target, APOC3, in its collaboration with Ionis Pharmaceuticals at
(NASDAQ:PMN), Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will be participating in a fireside chat and investor one-on-one meetings at the 8th Annual
(NYSE:TRGP), $1.25 billion purchase price represents ~6 times 2026 estimated unlevered adjusted free cash flow Underpinned by long-term acreage dedications of ~170,000 acres and attractive fee-based contracts Stable volume profile with significant additional economic drilling opportunities Further enhances Targa's leading sour gas treating capabilities and expands Targa's gathering and processing (G&P) footprint in the Permian
(NASDAQ:AKBA),(NASDAQ:QTTB), Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat, an sGC stimulator, initiated in focal segmental glomerulosclerosis (FSGS) Both trials planned to start treating subjects in 2026 CAMBRIDGE, Mass., Dec.
(NasdaqGM:NRIX), SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that the company will host a live webcast on Monday, December 8, 2025, at 8:15 p.m. ET, to
(TSX-V:NBY),(OTC US:NBYCF),(OtherOTC:NBYCF), NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MONTRÉAL, Dec. 01, 2025 (GLOBE NEWSWIRE) — NioBay Metals Inc. (TSX-V: NBY) (“NioBay” or the “Corporation“), is pleased to announced that it has entered into an agreement with Red Cloud Securities Inc. (“Red Cloud“) to act as
(TSX-V:BRW),(OTC US:BRWXF),(Other OTC:BRWXF),(Boerse Frankfurt – Freiverkehr:1XQ), MONTREAL, Dec. 01, 2025 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; “BRW” or the “Company“) is pleased to announce more results from its inaugural drilling campaign at the Anatacau Main Project, located in the Eeyou Istchee-James Bay region of Quebec. All results have now been received
(TSX-V:QTWO),(OTC US:QUEXF),(Other OTC:QUEXF),(Boerse Frankfurt – Freiverkehr:458),(Boerse Frankfurt – Freiverkehr:458.F), Highlights: Four (4) drill holes from the 2025 infill drill program with strong analytical results are reported herein: CS25-040: 12 separate intervals, including 95.1 metres (“m”) at 1.56% Li2O, 81.9 m at 1.56% Li2O and 66.5 m at 1.26% Li2O; CS25-041: seven (7) separate intervals, including